Publications by authors named "L Perreault"
Objective: Circulating lipids are linked with insulin resistance and increased cardiovascular disease risk. We previously reported that dihydroceramides, a specific type of sphingolipid, are elevated in insulin-resistant individuals; however, little is known regarding whether insulin-sensitizing lifestyle interventions can improve profiles of sphingolipids and other lipid species.
Methods: A total of 21 individuals with obesity participated in a 3-month lifestyle intervention of combined weight loss and exercise training.
Background: Obesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes.
View Article and Find Full Text PDFArticle Synopsis
- Intracellular accumulation of ceramide in muscle cells may be a key factor in insulin resistance linked to type 2 diabetes, particularly influenced by oxidised phosphatidylcholine found in oxidised LDL.
- A study involving 58 individuals showed that higher levels of oxidised phosphatidylcholine are associated with decreased insulin sensitivity and increased ceramide levels in skeletal muscle.
- Experiments on rat muscle cells revealed that specific oxidised phosphatidylcholine species, like POVPC, promote ceramide accumulation, trigger inflammation, and contribute to insulin resistance.
Background: The quantitative effects of congenital heart disease (CHD) risk factors are not fully understood. We conducted a meta-analysis of all CHD risk factors. This report explores maternal medication, assisted reproductive technologies (ART), and familial and fetal factors.
View Article and Find Full Text PDFTrends in COPD severe exacerbations, and all-cause and respiratory mortality, before and after implementation of newer long-acting bronchodilators in a large population-based cohort.
BMC Pulm Med
September 2024
Background: Little is known about the trends in morbidity and mortality at the population level that followed the introduction of newer once-daily long-acting bronchodilators for COPD. The purpose of the study was to evaluate whether the availability of new bronchodilators was associated with changes in the temporal trends in severe COPD exacerbations and mortality between 2007 and 2018 in the older population with COPD; and whether this association was homogeneous across sex and socioeconomic status classes.
Methods: We used an interrupted time-series and three segments multivariate autoregressive models to evaluate the adjusted changes in slopes (i.